Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome.

[1]  M. Voso,et al.  Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes , 2018, Leukemia.

[2]  M. Voso,et al.  The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia , 2017, Oncotarget.

[3]  M. Voso,et al.  Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[5]  M. Voso,et al.  Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real‐world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia , 2016, European journal of haematology.

[6]  R. Zini,et al.  Genomic landscape of megakaryopoiesis and platelet function defects. , 2016, Blood.

[7]  Hui Liu,et al.  Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes , 2016, Oncology letters.

[8]  X. Ke,et al.  High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia , 2016, Oncotarget.

[9]  J. Barnard,et al.  Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. , 2016, Leukemia research.

[10]  C. Jung,et al.  Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients , 2015, Oncotarget.

[11]  Ming-zhu Yin,et al.  MicroRNA-302b Suppresses Human Epithelial Ovarian Cancer Cell Growth by Targeting RUNX1 , 2014, Cellular Physiology and Biochemistry.

[12]  Joanna S Morris,et al.  Expression of RUNX1 Correlates with Poor Patient Prognosis in Triple Negative Breast Cancer , 2014, PloS one.

[13]  A. Giagounidis,et al.  Morphology, cytogenetics and classification of MDS. , 2013, Best practice & research. Clinical haematology.

[14]  M. Tijssen,et al.  Transcription factors in late megakaryopoiesis and related platelet disorders , 2013, Journal of thrombosis and haemostasis : JTH.

[15]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[16]  A. Baruchel,et al.  High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia. , 2012, Blood.

[17]  M. Odero,et al.  Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities , 2012, Leukemia.

[18]  Zongdong Li,et al.  The effect of decitabine on megakaryocyte maturation and platelet release , 2011, Thrombosis and Haemostasis.

[19]  A. Stamatoullas,et al.  Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. , 2011, Blood.

[20]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[21]  J. Martínez-López,et al.  Clinical significance of Gata‐1, Gata‐2, EKLF, and c‐MPL expression in acute myeloid leukemia , 2009, American journal of hematology.

[22]  M. Kacena,et al.  Human phenotypes associated with GATA-1 mutations. , 2008, Gene.

[23]  H. Kantarjian,et al.  The incidence and impact of thrombocytopenia in myelodysplastic syndromes , 2007, Cancer.

[24]  E. Hoffman,et al.  Decreased platelet expression of myosin regulatory light chain polypeptide (MYL9) and other genes with platelet dysfunction and CBFA2/RUNX1 mutation: insights from platelet expression profiling , 2007, Journal of thrombosis and haemostasis : JTH.

[25]  H. Harigae.  GATA transcription factors and hematological diseases. , 2006, The Tohoku journal of experimental medicine.

[26]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[27]  B. Kahaleh,et al.  Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. , 2006, Arthritis and rheumatism.

[28]  M. Weiss,et al.  Megakaryocyte biology and related disorders. , 2005, The Journal of clinical investigation.

[29]  M. Lübbert,et al.  The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. , 2004, Leukemia research.

[30]  W. Vainchenker,et al.  FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. , 2004, The Journal of clinical investigation.

[31]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  G. Blobel,et al.  Control of megakaryocyte‐specific gene expression by GATA‐1 and FOG‐1: role of Ets transcription factors , 2002, The EMBO journal.

[33]  S. Cheong,et al.  GATA-1 and GATA-2 gene expression is related to the severity of dysplasia in myelodysplastic syndrome , 2002, Leukemia.

[34]  R Favier,et al.  Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. , 2000, Immunity.

[35]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[36]  Stuart H. Orkin,et al.  An early haematopoietic defect in mice lacking the transcription factor GATA-2 , 1994, Nature.

[37]  C. Abildgaard,et al.  Thrombopoiesis. , 2020, Seminars in hematology.